key: cord-0843490-ggs9gsiv
authors: Mañón, Victoria A.; Balandran, Steven; Young, Simon; Wong, Mark; Melville, James C.
title: COVID-Associated Avascular Necrosis of the Maxilla - A Rare, New Side Effect of COVID-19
date: 2022-05-06
journal: J Oral Maxillofac Surg
DOI: 10.1016/j.joms.2022.04.015
sha: d20e487abf9cac13f26bdf5a5ef23627f90c0d8c
doc_id: 843490
cord_uid: ggs9gsiv

Purpose The purpose of this article is to present an interesting, rare case of a patient that experienced avascular necrosis of the maxilla associated with COVID-19 infection. Methods and Results Our team retrospectively evaluated this patient’s chart after completion of surgical management. The patient is a 72-year old male that presented to the University of Texas Health Science Center at Houston for surgical management of his infarcted maxilla, which developed as a sequela of infection with COVID-19. A literature review was completed using PubMed. Twenty-five articles are reviewed and discussed. Conclusion Infection with COVID-19 confers a hypercoagulable state in patients, leading to various complications in the head and neck region. In our case report, we present a patient that developed avascular necrosis of the maxilla secondary to infection with COVID-19. Thromboembolic prophylaxis is imperative in COVID-19 patients due to the high rate of potential systemic complications.

While colloquially thought of as a pulmonary disease, complications associated with COVID-19 infection have been observed in multiple other organs, including the heart, kidneys, and head and neck region. A systemic complication of COVID-19 is the development of a hypercoagulable state, which can lead to the development of thrombo-emboli and subsequently cerebral infarctions and myocardial infarctions. In the head and neck region, an observable occlusion on computed tomography angiography (CTA) has not been reported.

The aim of this article is to present a unique case of bilateral maxillary necrosis resulting from occlusion of the left internal maxillary artery secondary to COVID-19 infection. This phenomenon was confirmed with a CTA demonstrating occlusion of the left internal maxillary artery and branches of the pterygoid plexus. Surgical management of this patient and the pathophysiology based on available literature is reviewed. It is important for the head and neck surgeon to understand the pathophysiology of a hypercoagulable state induced by COVID-19 infection, how this affects the head and neck region, and how to prevent this complication in the perioperative period.

In January 2021, a 72-year-old male with a past medical history significant for persistent atrial fibrillation (Afib; status post ablation in 2009 and on daily 5mg of warfarin), diabetes mellitus type II, coronary artery disease, and hypertension presented to an outside hospital with a chief complaint of headaches, blurry vision in the left eye, loss of taste, and an upper respiratory tract infection. His presenting international normalized ratio (INR) was 4.5. The patient's condition quickly deteriorated due to COVID-related pneumonia and he was hospitalized in the intensive care unit (ICU) for approximately 1 month. Venous thromboembolism (VTE) prophylaxis included continuation of the Warfarin at a therapeutic level and sequential compression devices (SCDs). Temporal arteritis, cerebrovascular infarction, bilateral internal carotid stenosis, and deep vein thrombosis were ruled out via biopsy, CT head without contrast, carotid artery duplex scan, and bilateral lower extremity venous duplex, respectively. During the hospitalization, he also began to develop exposed bone in the right and left maxilla. After recovery, he was discharged from the hospital on 5mg of apixaban BID and 81mg of aspirin daily. He reports daily compliance with all medications.

After hospital discharge, he presented to a local oral and maxillofacial surgeon in May 2021 for the exposed bone of the maxilla. He was subsequently referred to the University of Texas Health Science Center at Houston (UTHSC-H), Oral and Maxillofacial Surgery (OMFS) Department; he presented to the clinic in September 2021. No treatment was initiated prior to the referral; the patient attributed the delays in treatment to issues with insurance and finances.

Clinical exam revealed an edentulous maxillary ridge with exposed, infarcted bone on the labiobuccal surface extending from the left posterior maxilla anteriorly to the left canine region, and from the keratinized gingiva mid-height of the alveolus to the depth of the vestibule. An isolated, 8 mm x 8 mm segment of infarcted bone was also present on the labial surface of the right maxilla in the premolar region ( Figure 1 ). The bone was mildly suppurative. The patient endorsed hypoesthesia in the distribution of left cranial nerve V-2; cranial nerve VII was grossly intact bilaterally. A maxillofacial CT without contrast revealed osteolytic changes of the hard palate, superior alveolar ridge, left maxilla, zygoma, zygomatic arch, left ethmoid air cells (lamina papyracea), pterygoid plates, and pterygoid palatine fissure ( Figure 2A , 2B, 2C, 2D). A neck CTA demonstrated an abrupt cut-off of a small branch of the left internal maxillary artery located adjacent to the medial aspect of the left mandible, representing occlusion ( Figure 3 [YS2] ). Additionally, the left pterygoid plexus was non-filling, indicating further occlusion of these branches.

The patient was taken to surgery and underwent debridement of the maxilla ( Figure 4A , 4B). Cultures were obtained, yielding moderate Pseudomonas aeruginosa, moderate Klebsiella pneumoniae (with resistance to ampicillin), few Candida tropicalis, and few Enterococcus species. Biopsy of the specimen confirmed osteonecrosis of the maxilla. Primary closure was achieved ( Figure 5 ). The patient was placed on amoxicillin/clavulanic acid 875mg-125mg BID for 10 days. The patient continued his regimen of apixaban 5mg every 12 hours. The UTHSC-H OMFS surgical team continues to follow the patient after surgical intervention.

Emerging complications of COVID-19 in the maxillofacial region are being observed. It has been noted that patients treated for COVID-19 are at higher risk for complications secondary to thromboemboli and fungal infections, including mucormycosis. The etiology of these complications is multifactorial and includes medication side effects, damage to endothelial cells, patient immobility, and other factors related to critical illness (15, 16) . This patient demonstrated concerns for both of these complications. The authors of this paper believe this patient experienced multiple thromboemboli, as evidenced by the CT angiography, and the exam results that ruled out giant cell temporal arteritis, DVTs, and CVA. Complications from the thromboemboli include the patient's visual disturbances and necrosis of the maxilla. With a high suspicion for invasive fungal species, several biopsies and cultures were sent of our patient; no fungal contamination or colonization was found. It is also plausible that the prescribed anticoagulation was insufficient for the hypercoagulable state induced by COVID-19 infection.

There have only been a few reported cases of necrosis or osteomyelitis of the jaw after COVID-19 infection. One case series detailed osteomyelitis or necrosis of the maxilla in a series of four patients who had contracted COVID-19 (17) . Another case report detailed maxillary necrosis in a single patient following COVID-19 infection (18) . Other oral cavity manifestations have been described including oral ulcers, petechiae, reddish spotting of the palate, desquamative gingivitis and blisters (17) . No reported cases have described thrombosis of the internal maxillary artery.

Accumulating data suggests that COVID-19 infection can predispose one to a hypercoagulable state, increasing the risk for both arterial and venous thrombosis. A high incidence of thrombotic complications has been documented in the literature. There have been a number of reports for arterial thrombosis. In one large study of 3335 hospitalized patients with COVID-19, thrombotic events occurred in 16% of patients. Arterial events included ischemic stroke (1.6%), systemic thromboembolism (1.0%), and myocardial infarction (8.9%) (25) . The pathogenesis of this prothrombotic state is currently incompletely understood. A myriad of factors may play a role and different mechanisms have been proposed. Consequently, this phenomenon has been termed "COVID associated coagulopathy" (CAC) (22) .

Endothelial injury and dysfunction (endotheliopathy) play a role in COVID-19 thrombosis and coagulopathy. Autopsy studies have shown endothelial inflammation (2) after COVID-19 infection. Marked increases of endothelial activation and injury markers including vonWillebrand factor (vWF), angiopoietin 2, P-selectin, and thrombomodulin have been noted, where vWF and thrombomodulin correlate with mortality (1, 3, 8, 9, 10) . COVID-19 may directly (through the ACE2 receptor) or indirectly trigger endothelial exocytosis of prothrombotic/ pro-inflammatory factors which drives microvascular inflammation and thrombosis (3) . Hyperactivation of the complement system has been seen in COVID-19, with increased circulating markers correlating with severe disease. Thrombotic microvascular injury with extensive deposition of complement proteins has been seen in autopsy (4) . Activation of complement may be direct from COVID-19 or as a sequela of endotheliopathy which in turn activates the complement system (5) . In line with this, studies of Middle East Respiratory Syndrome coronavirus in C3-deficient mice or in those with blockage of the distal complement system show less systemic pathology (6) (7) . Terminal components of the complement cascade may promote endothelial injury and dysfunction through multiple processes (5). Complement system targets are currently being studied.

Laboratory analysis has been consistent with a hypercoagulable state in COVID-19. Increased Ddimer, fibrinogen, Factor VIII, von Willebrand factor and decreased antithrombin have been noted in the critically ill (11, 12) . In addition, thromboelastography (TEG) results are consistent with a state of hypercoagulability, with shortened reaction time (R) & clot formation time (K), increased maximum amplitude (MA), and decreased clot lysis at 30 minutes (LY30) (11) . Although critical illness is known to cause a hypercoagulable state, COVID-19 appears to cause a profoundly pro-inflammatory state, escalating pro-thrombotic factors (13) . In addition, plasma hyper-viscosity has been observed in critically ill patients with COVID-19 pneumonia (14) . Neutrophil extracellular traps, web-like structures of chromatin, proteins and oxidant enzymes, have been described as also possibly contributing to immunothrombosis (19, 20) . These factors have been confirmed to cause thromboembolism despite appropriate thromboembolic prophylaxis (21, 22) .

Venous thromboembolic (VTE) prophylaxis is imperative given the elevated risk of complications. The NIH COVID prophylactic guidelines are in Table 1 (23) . The use of therapeutic-vs. prophylactic doses of anticoagulation have been reviewed in clinical trials. In ICU settings, therapeutic heparin did not reduce mortality and may lead to higher risk of bleeding events, therefore standardized use of therapeutic doses of heparin is not recommended. Other trials (RAPID and HEP-COVID trials) evaluated VTE prophylaxis in non-ICU COVID-19 patients and found that therapeutic doses of heparin may be beneficial in patients that have elevated D-dimer levels, require low-flow oxygen, and have no increased bleeding risks. The use of direct oral anticoagulants (DOACs) has also been reviewed; Testa et al (2020) found that the simultaneous use of DOACs and antiviral medications can lead to supratherapeutic levels of DOAC, therefore the authors recommended the transition from DOACs to LMWH or UFH if antiviral therapy is necessary (22, 24) . There are clinical trials currently investigating the use of antiplatelets for the use of CAC. The concomitant use of corticosteroids and nonsteroidal antiinflammatory medications in addition to prophylaxis has limited and/or conflicting evidence to support their use (22, 23) . In February 2021, the American Society of Hematology guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 suggested the use of prophylacticintensity over therapeutic-intensity anticoagulation for patients with COVID-19.

Thromboembolism of the internal maxillary artery secondary to a hypercoagulable state from COVID-19 infection can lead to bilateral maxillary necrosis. Infection with COVID-19 and immobility can increase the complication risks of hospitalized patients, even with prophylactic doses of anticoagulation therapy. In this report, we document this complication, confirmed with CTA and biopsy of the maxilla. Other potential causes of necrosis and ophthalmologic complications (giant cell arteritis, CVA) were ruled out. The pathophysiology of COVID-induced hypercoagulability is caused by multiple factors, including an increase in D-dimer, fibrinogen, Factor VIII, von Willebrand factor, and a decrease in antithrombin. Other cellular changes, including neutrophil extracellular traps and changes in enzymatic proteins and oxidants, may also contribute. These changes are exacerbated in the critically-ill, immobile patient. If necrosis of the maxilla, or any other bony structure develops, the patient should be managed surgically; biopsy and cultures should be obtained to rule out superimposed infections and confirm diagnosis. NIH guidelines for VTE prophylaxis should be reviewed by the surgeon and managing team to prevent potential complications. Figure 1 . Clinical photo from the patient's initial presentation to the UTHSC-H OMFS clinic. There is necrotic, exposed bone on the labio-buccal surfaces of the left and right maxillary quadrants with suppuration. Figure 2A . Axial view. There are osteolytic changes seen to the hard palate, superior alveolar ridge, and left maxilla. Figure 2B . Axial view. There are osteolytic changes seen to the left maxilla, zygoma, and left ethmoid air cells. Figure 2C . Coronal view. There are osteolytic changes seen to the hard palate, superior alveolar ridge, left maxilla, zygoma, zygomatic arch and left ethmoid air cells. Figure 2D . Sagittal view. There are osteolytic changes seen to the hard palate, superior alveolar ridge, left maxilla, and left ethmoid air cells. 

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

Endothelial cell infection and endotheliitis in COVID-19

Severe covid-19 is a microvascular disease

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

The state of complement in COVID-19

Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV

Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Endothelial cells orchestrate COVID-19 coagulopathy

Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

Rhinocerebral mucormycosis as a sequelae of covid-19 treatment: a case report & literature review

Maxillary mucormycosis osteomyelitis in post covid-19 patients: a series of fourteen cases

Complications of COVID-19 in the maxillo-facial region: Clinical case and review of the literature

Aspects of maxillar osteomyelitis in patients who had COVID-19 in Uzbekistan

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Neutrophil extracellular traps in COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?

Department of Health and Human Services. (n.d.). Statement on anticoagulation in hospitalized patients

Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience

Thrombosis in hospitalized patients with covid-19 in a new york city health system